Navigation Links
Study examines treatments for relieving breathing difficulties among patients with lung effusions
Date:5/20/2012

Helen E. Davies, M.D., of the University Hospital of Wales, Cardiff, and colleagues compared the effectiveness of treatments to relieve breathing difficulties among patients with malignant pleural effusion (presence of fluid in the pleural cavity [space between the outside of the lungs and the inside wall of the chest cavity], as a complication of malignant disease). The treatments compared were chest tube drainage and talc slurry for pleurodesis (a procedure in which the pleural space is obliterated) vs. indwelling pleural catheters (IPCs).

Malignant pleural effusion causes disabling dyspnea (breathing difficulties) in more than 1 million people worldwide annually; patients have an average life expectancy of 4 months. "There are no robust clinical data to address which of these treatments is more effective at palliating symptoms and improving quality of life," the authors write. "Indwelling pleural catheters are increasingly used as an alternative treatment to talc pleurodesis."

The randomized controlled trial compared IPC (n = 52) and talc slurry for pleurodesis (n = 54) for patients with malignant pleural effusion who were treated at 7 U.K. hospitals. Patients were screened from April 2007-February 2011 and were followed up for a year. The researchers found that there was no significant difference between groups in dyspnea in the first 42 days after intervention. Indwelling pleural catheters reduced time in the hospital but were associated with an excess of adverse events. "As such, IPCs cannot be advocated as a superior treatment to talc pleurodesis for palliation of symptoms," the authors write.


'/>"/>

Contact: Najib M. Rahman
najib.rahman@ndm.ox.ac.uk
JAMA and Archives Journals
Source:Eurekalert

Page: 1

Related medicine news :

1. Study evaluates use of inhaled saline for young children with cystic fibrosis
2. Study says children exposed to tobacco smoke face long-term respiratory problems
3. One-Third of U.S. Homeless Population Is Obese: Study
4. Military Marriages Stay Strong in Face of Challenges: Study
5. Its Not Just What You Eat, Its When You Eat, Mouse Study Finds
6. Parents Often Lose Sleep Over Childs Epilepsy, Study Finds
7. OSHAs Safety Tests Protect Workers at Little Cost: Study
8. Scientists study serious immune malfunction
9. Study Explores Distractions Role in Pain Relief
10. Early Study Hints at Link Between Certain Sunscreens, Endometriosis
11. Researchers undertake radical new cancer survivorship study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... ... 22, 2017 , ... Silicon Valley startup Enke Life has ... Their electric toothbrushes aggressively attack oral bacteria by reducing dental plaque and other ... edge Enke technology with a premium timeless design, they want to redefine the ...
(Date:9/22/2017)... ... September 22, 2017 , ... Egg ... life. Although frozen embryos have a slight statistical advantage for live births, frozen ... a wonderful opportunity for women undergoing medical treatment or who are concerned about ...
(Date:9/21/2017)... ... September 21, 2017 , ... Process Capability Indices for ... 3:00 p.m. ET, http://www.fdanews.com/processcapabilityindices      , Quality in device ... of The Quality System Regulation (§820.250), and Devicemakers find themselves staring at a ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... of a new member survey conducted by the International Society of Hair ... from 2014 to 2016 rose 60 percent, with 635,189 procedures performed in 2016. ...
(Date:9/21/2017)... ... 21, 2017 , ... Innovatum will demonstrate capabilities of fully ... Conference 2017 in Chicago, IL on October 17-19, 2017. This unique development addresses ... patient safety. , Microscan , a global technology leader in barcoding, ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly and ... will present new data for galcanezumab and lasmiditan, two ... the International Headache Society (IHC) taking place Sept. 7-10 ... Lilly will highlight new, long-term data from an open-label ... of galcanezumab (120 mg and 240 mg) for the ...
(Date:9/5/2017)... , Sept. 5, 2017 Oramed Pharmaceuticals Inc. ... ), a clinical-stage pharmaceutical company focused on the development ... has successfully concluded its meeting with the U.S. Food ... oral insulin formulation. ... the regulatory pathway for submission of ORMD-0801, would be ...
(Date:8/29/2017)... , Aug. 29, 2017 ivWatch, LLC, the leading provider ... infiltrations, announced it has been awarded an Innovative Technology contract from ... the country. ... device to aid in the early detection of peripheral IV infiltration ... The Innovative Technology contract ...
Breaking Medicine Technology: